Optimer Pharmaceuticals, Inc.
Optimer Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has made significant strides in developing innovative therapies, particularly in the fields of gastrointestinal and infectious diseases. With a focus on advancing patient care, Optimer is renowned for its flagship product, Dificid (fidaxomicin), which offers a unique treatment option for Clostridium difficile infections. Operating primarily in North America and expanding its reach globally, Optimer Pharmaceuticals has established a strong market position through its commitment to research and development. The company’s dedication to addressing unmet medical needs has garnered recognition within the industry, solidifying its reputation as a leader in specialised pharmaceuticals.
DitchCarbon Score
How does Optimer Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Optimer Pharmaceuticals, Inc.'s score of 27 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Optimer Pharmaceuticals, Inc.'s reported carbon emissions
Optimer Pharmaceuticals, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action within the pharmaceutical industry. As the sector increasingly focuses on sustainability, it is essential for companies like Optimer to establish clear climate commitments and reduction strategies to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Optimer Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
